Baxter BioScience

Baxter's BioScience business is a leader in recombinant and plasma protein replacement therapies for the treatment of hemophilia and other bleeding disorders; plasma-based therapies for the treatment of immune deficiencies, alpha-1 antitrypsin deficiency, burns and shock, as well as other chronic and acute blood-related conditions; biosurgical products and development technologies for adult stem cell therapy; and vaccines. The core franchises of BioScience include: hemophilia, biotherapeutics, biosurgery, and vaccines. BioScience products account for approximately 45% of Baxter's annual sales, totaling $5.7 billion in 2010. BioScience is a fully integrated enterprise, encompassing discovery, development, manufacturing, operations, and commercial ventures in fields such as coagulation therapy, immunoglobulin immune disorders, alpha-1 antitrypsin deficiency treatment, wound healing vaccines and treatments, and shock therapy.